Clinical trials: Post-menopausal
Breast Cancer
Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients
Endocrine therapy is the mainstay of systemic treatment in patients with endocrine responsive breast cancer. Aromatase inhibitors are the most active agents in post-menopausal women.
- Trial name
- NCT00954135
- Testing
- letrozolo+cyclophosphamide, letrozolo+sorafenib+cyclophosphamide
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- University of Turin, Italy
Osteoporosis, Post-Menopausal
PTH Comparison in Post Menopausal Women
Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
- Trial name
- NCT00543218
- Testing
- teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous
- Where
- 4 sites in Taiwan
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Trace Elements Levels After Breast Cancer Radiotherapy
Effect of Aerobic Exercises on Trace Elements in Post-menopausal Women After Radiotherapy
This study will be conducted on 28 participants who are survivors of breast cancer and underwent radiotherapy. The purpose of the current study is to investigate the effect of aerobic exercises on quality of life and serum levels…
- Trial name
- NCT06070155
- Testing
- Aerobic Exercise three time a week
- Where
- Egypt
- Volunteers
- 28 people
- Sponsor
- Cairo University
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Osteoporosis, Osteopenia
Periodontal Disease and Post-menopausal Osteoporosis
The aim of this study was to investigate the levels of RANKL and Osteoprotegerin, and their relationship in gingival crevicular fluid of post-menopausal women with osteoporosis/osteopenia and chronic periodontitis simultaneously…
- Conditions
- Osteoporosis, Osteopenia, Periodontal Disease
- Trial name
- NCT02184962
- Where
- Argentina
- Volunteers
- 81 people
- Sponsor
- Universidad Nacional de Córdoba
Hot Flashes, Hot Flushes
Stellate Ganglion Blockade in Post-Menopausal Women
Hot flashes and night sweats (vasomotor symptoms, VMS) affect 80% of women during the menopausal transition (MT). VMS are associated with decreased quality of life, increased depressive and anxiety symptoms, memory complaints…
- Conditions
- Hot Flashes, Hot Flushes, Vasomotor Symptoms
- Trial name
- R01 (NCT02907983)
- Testing
- Stellate Ganglion Block Injection with Bupivicaine, Saline injection
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwestern University
Post-menopausal Women, Overweight and Obesity
Effect of (Poly)Phenolic on Cardiometabolic Risk of Postmenopausal Women
The purpose of this investigation is to test the hypothesis that in post-menopausal women with cardiometabolic risk, eating a relatively high daily amount of (poly)phenol-containing products (green tea, dark chocolate and…
- Trial name
- CARDIOGENE (NCT05255367)
- Testing
- (poly)phenols rich foods
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Universidad de Murcia
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Osteoporosis, Osteopenia
Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women
Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis.
- Trial name
- NCT00244907
- Testing
- Genistein vs Risedronate
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Purdue University
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Stress Urinary Incontinence
Vesair Balloon Confirmatory Trial (VECTOR)
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months.
- Trial name
- VECTOR (NCT03794206)
- Testing
- Vesair Balloon
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Solace Therapeutics, Inc.
Menopause, Sexual Dysfunction
Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause
Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of…
- Conditions
- Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
- Trial name
- TESTA MIND (NCT07408440)
- Testing
- Transdermal testosterone gel
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Hypertension (HTN)
NR and Exercise for Blood Pressure
Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve…
- Trial name
- NCT07475208
- Testing
- Brisk walking, Nicotinamide Riboside 1000 mg
- Volunteers
- 112 people
- Sponsor
- ZHANG Jiaqi
Osteopenia, Osteoporosis
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens.
- Trial name
- NCT01406548
- Testing
- BPS804 20mg/Kg
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Hand Osteoarthritis
Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?
Post-menopausal women aged 40-65 with symptomatic hand osteoarthritis are invited to take part in this feasibility study. The study's aim is to investigate whether it is acceptable to women with painful hand OA to take an…
- Trial name
- HOPE-e (NCT04036929)
- Testing
- Estrogen-bazedoxifene
- Where
- 3 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- University of Oxford
Osteoporosis
Assessment of Anti-RANKL Antibody in Post-menopausal Women
This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single dose subcutaneous injection of a fully human monoclonal antibody of receptor…
- Trial name
- NCT03242512
- Testing
- TK006
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Metastatic Breast Cancer
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Post-menopausal women with hormone-receptor positive (HR+) metastatic breast cancer resistant to aromatase inhibitor (AI) therapy will be randomized to receive Fulvestrant (Faslodex) with Everolimus or Fulvestrant (Faslodex) with…
- Trial name
- PrE0102 (NCT01797120)
- Testing
- Fulvestrant, Everolimus
- Where
- 25 sites in United States
- Volunteers
- 131 people
- Sponsor
- PrECOG, LLC.
Invasive Breast Cancer
AKT Inhibitor in Oestrogen Positive Breast Cancer
To compare the effect of four and a half days treatment of a range of doses of AZD5363 on selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen receptor positive breast cancers.
- Trial name
- STAKT (NCT02077569)
- Testing
- AZD5363
- Where
- 11 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University of Nottingham